A window to IBD

Oncostatin M: a new biomarker and target in IBD

An academia-industry collaboration has identified the cytokine oncostatin M (OSM) as possibly the first biomarker for predicting whether a patient with inflammatory bowel disease (IBD) will respond to anti-tumor necrosis factor α (TNFα) therapy.

In a Nature Medicine study published last

Read the full 406 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE